Avivagen Inc. (VIV:TSX.V), a company that is developing and commercializing products for livestock, companion animal and human applications to safely support immune function and promote general health and performance, has announced that its partner in the Philippines, UNAHCO, has purchased 2 metric tons of OxC-beta Livestock. This follows an order of 2 metric ton delivered to UNAHCO in June 2018.
"This second, significant purchase is a validation from UNAHCO's customers of the positive results from the adoption of OxC-beta Livestock," stated Avivagen. "UNAHCO continues to reaffirm its intention of making quarterly purchases of OxC-beta Livestock, resulting in a growing and recurring revenue stream for Avivagen."
OxC-beta Livestock is a proprietary product that the company says has been shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. The product is available for sale in the Philippines, Taiwan, Thailand and New Zealand.
The company stated that it intends to "accelerate market access and the commercial uptake of its OxC-beta Livestock product, a product that has the potential to eliminate the use of antibiotics as growth promoters in livestock feed, which is a problem that needs an urgent solution and which represents a multi-billion dollar market opportunity."
UNAHCO is the exclusive distributor for Avivagen's OxC-beta Livestock in the Philippines, where it now allowed to be used in all food animal species. "The Philippines is an important feed market, with an estimated annual feed production of 17 million metric tons for 2017, up dramatically from 11.75 million metric tons in 2016," the company noted.
UNAHCO is the wholly owned feed and veterinary subsidiary of Unilab Inc., the biggest pharmaceutical company in the Philippines.
"UNAHCO provides a broad range of animal healthcare and nutrition products and programs to meet the requirements of both commercial and individual farmers in the Philippines as well as abroad. It is a leading producer of pig and poultry feed and has a distribution network that serves more than 3,000 outlets, supported by more than 100 field personnel," noted Avivagen.
Read what other experts are saying about:
Disclosure:
1) John McPhaul compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an employee. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen Inc. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen Inc. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen Inc., a company mentioned in this article.
